...
首页> 外文期刊>Journal of experimental & clinical cancer research : >Gene expression profile of multiple myeloma cell line treated by realgar.
【24h】

Gene expression profile of multiple myeloma cell line treated by realgar.

机译:雄黄处理的多发性骨髓瘤细胞系的基因表达谱。

获取原文
获取原文并翻译 | 示例
           

摘要

In order to elucidate the molecular mechanism of Realgar treatment for multiple myeloma (MM), cDNA microaaray was used to compare the gene expression profiles of MM cell line RPMI8226 at 72 hrs pre- and post-Realgar treatment on three separate days. 54 up-regulated and 60 down-regulated genes were identified by cDNA microarray. Further analysis screened out 17 up-regulated and 3 down-regulated genes with Z-score greater than 2 or less than -2, which can be considered the significantly altered genes after Realgar treatment in this study. CCL2, CCL3, BTG1,TNFAIP3, TNFAIP8, SLC38A2, IGFBP4 were important up-regulated genes and they were associated with a variety of cell life functions such as cell growth, cell-cell signaling, regulation of apoptosis and cell homeostasis based on biological process of gene. There are only 3 significantly down-regulated genes (Z-score <-2.0) involved in muscle contract. Several of these genes have been previously identified in relation to MM in published papers. Subsequent validation of selected genes (CCL2, TNFAIP3 and BTG1) by reverse transcription polymerase chain reaction was consistent with our microarray analysis. CCL2 may be involved in MM pathobiology by tumor growth suppression. BTG1 could be used as a potential treatment-related biomarker for monitoring the therapy effect and the remission status of leukemia patients.
机译:为了阐明Realgar治疗多发性骨髓瘤(MM)的分子机制,使用cDNA microaaray比较了在Realgar治疗前后72小时(分别在三天)MM细胞系RPMI8226的基因表达谱。通过cDNA微阵列鉴定出54个上调基因和60个下调基因。进一步的分析筛选出Z值大于2或小于-2的17个上调基因和3个下调基因,在本研究中,这可以认为是雄黄素处理后显着改变的基因。 CCL2,CCL3,BTG1,TNFAIP3,TNFAIP8,SLC38A2,IGFBP4是重要的上调基因,它们与多种细胞生命功能相关,例如细胞生长,细胞信号转导,细胞凋亡调节和基于生物过程的细胞稳态基因。肌肉收缩仅涉及3个显着下调的基因(Z分数<-2.0)。这些基因中的一些先前已在发表的论文中与MM相关地鉴定出来。随后通过逆转录聚合酶链反应对所选基因(CCL2,TNFAIP3和BTG1)的验证与我们的微阵列分析一致。 CCL2可能通过抑制肿瘤生长而参与MM病理学。 BTG1可用作潜在的治疗相关生物标志物,以监测白血病患者的治疗效果和缓解状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号